BMC CANCER

Scope & Guideline

Advancing the Frontiers of Cancer Research

Introduction

Explore the comprehensive scope of BMC CANCER through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore BMC CANCER in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationBMC CANCER / BMC Cancer
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

BMC CANCER is dedicated to publishing high-quality research articles covering the broad spectrum of cancer research. The journal focuses on studies that advance our understanding of cancer biology, treatment, and prevention, with a strong emphasis on translational research and clinical implications.
  1. Cancer Biology and Mechanisms:
    Research exploring the molecular and cellular mechanisms underlying cancer development and progression, including studies on genetic mutations, epigenetic changes, and tumor microenvironment interactions.
  2. Clinical Oncology and Treatment Strategies:
    Investigations into various treatment modalities for cancer patients, including chemotherapy, radiotherapy, immunotherapy, and novel therapeutic agents, along with studies assessing treatment efficacy and safety.
  3. Epidemiology and Public Health:
    Studies addressing cancer epidemiology, including risk factors, incidence, prevalence, and survival rates, particularly in diverse populations and underrepresented communities.
  4. Biomarkers and Early Detection:
    Research focused on identifying novel biomarkers for cancer diagnosis, prognosis, and treatment response, as well as studies on screening methods and technologies for early cancer detection.
  5. Patient-Centered Outcomes:
    Investigations into health-related quality of life, patient experiences, and psychosocial aspects of cancer care, highlighting the importance of patient perspectives in oncology.
  6. Translational Research:
    Studies bridging laboratory findings with clinical applications, aiming to translate basic research discoveries into effective cancer therapies and improved patient outcomes.
BMC CANCER is witnessing several emerging themes that reflect the evolving landscape of cancer research. These trends indicate a shift towards more integrative and patient-focused approaches in oncology.
  1. Immunotherapy and Immune Profiling:
    Research on immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapies, is rapidly increasing, focusing on understanding immune responses and patient stratification based on immune profiles.
  2. Microbiome and Cancer Relationships:
    An emerging area of interest is the relationship between the microbiome and cancer, with studies exploring how gut microbiota influences cancer development, treatment responses, and patient outcomes.
  3. Precision Medicine and Genomic Profiling:
    There is a growing emphasis on precision medicine, with researchers focusing on genomic profiling to tailor treatments based on individual patient characteristics and tumor genetics.
  4. Patient-Reported Outcomes and Quality of Life:
    Increasing attention is being paid to patient-reported outcomes and quality of life assessments, emphasizing the importance of holistic care and survivorship issues in cancer management.
  5. Artificial Intelligence and Machine Learning in Oncology:
    The integration of AI and machine learning techniques in cancer research is gaining traction, with applications in early detection, treatment prediction, and personalized therapy planning.
  6. Long Non-Coding RNAs in Cancer:
    Research into long non-coding RNAs as potential biomarkers and therapeutic targets is on the rise, reflecting a broader interest in the regulatory roles of non-coding RNA in cancer biology.

Declining or Waning

While BMC CANCER continues to thrive in various areas, certain themes have shown a decline in recent publications, indicating a shift in focus within the cancer research community.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in studies solely focused on traditional chemotherapy regimens, as the field shifts towards exploring combination therapies and personalized treatment approaches.
  2. Basic Science without Clinical Relevance:
    Research articles that focus exclusively on basic science findings without clear clinical implications are becoming less prevalent, as the emphasis now leans towards translational research with direct applications in patient care.
  3. Single-Institution Studies:
    The trend is moving away from single-institution studies towards multi-center collaborations and larger cohort analyses, which provide more generalizable results and insights.
  4. Longitudinal Studies without Novel Insights:
    Longitudinal studies that do not introduce new methodologies or significant findings related to cancer treatment or patient outcomes are less frequently published, reflecting a preference for innovative research.

Similar Journals

CANCER AND METASTASIS REVIEWS

Fostering Innovation in Cancer Treatment Strategies
Publisher: SPRINGERISSN: 0167-7659Frequency: 4 issues/year

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Nature Cancer

Exploring the Complexities of Cancer Treatment
Publisher: NATURE PORTFOLIOISSN: Frequency: 12 issues/year

Nature Cancer, published by NATURE PORTFOLIO, stands at the forefront of oncological research with a robust impact within the scientific community. As an esteemed journal with impressive rankings—#12 in Medicine (Oncology) and #8 in Biochemistry, Genetics and Molecular Biology (Cancer Research) according to Scopus, placing it within the 97th and 96th percentiles respectively—Nature Cancer boasts a Q1 category status in both Cancer Research and Oncology for 2023. The journal's commitment to advancing cancer research is crucial, promoting high-quality, peer-reviewed studies that address the complexities of cancer biology and treatment. By facilitating open access to impactful findings, Nature Cancer aims to foster collaboration and inspire innovative approaches among researchers, professionals, and students alike, making significant strides in the global fight against cancer. As this pivotal publication continues its converged years from 2020 to 2024, it heralds a future ripe with transformative insights and breakthroughs in the vital field of oncology.

Breast Cancer

Exploring the latest in breast cancer science and care.
Publisher: SPRINGER JAPAN KKISSN: 1340-6868Frequency: 6 issues/year

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Cancer Reports

Championing innovation in oncology research.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Frontiers in Oncology

Pioneering new frontiers in cancer knowledge and treatment.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

CANCER INVESTIGATION

Exploring the frontiers of cancer research with precision.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

CANCER CELL

Empowering the Fight Against Cancer
Publisher: CELL PRESSISSN: 1535-6108Frequency: 12 issues/year

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

ORAL ONCOLOGY

Fostering Innovation in Oral Cancer Studies
Publisher: ELSEVIERISSN: 1368-8375Frequency: 12 issues/year

ORAL ONCOLOGY is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of oncology with a specific focus on oral diseases and cancers. Since its inception in 1996, this esteemed journal has provided a platform for high-quality research that addresses critical issues in oral surgery, cancer research, and related disciplines. With impressive rankings in Q1 in Oncology and Q1 in Oral Surgery, and recognized as Rank #1 in Dentistry and Oral Surgery by Scopus, ORAL ONCOLOGY consistently publishes impactful articles that contribute significantly to our understanding of oral cancers. The journal is committed to sharing pioneering findings that enhance clinical practices and improve patient outcomes. As a non-open access journal, it provides readers with exclusive access to cutting-edge research, ensuring that professionals, researchers, and students are at the forefront of developments in the field. Situated in the United Kingdom, ORAL ONCOLOGY serves as an indispensable resource for those dedicated to advancing oral health and oncology research through rigorous scientific inquiry and collaboration.

Oncology Letters

Exploring New Frontiers in Cancer Treatment and Care
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Championing Excellence in Cancer Research and Clinical Practice.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.